Abcam, ab123490, Anti-EHHADH antibody

Size: 100µg
Rabbit Polyclonal EHHADH antibody. Suitable for IP, WB and reacts with Human samples. Cited in 3 publications. Immunogen corresponding to Synthetic Peptide within Human EHHADH aa 650 to C-terminus.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human EHHADH aa 650 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.Q08426

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7 - 8Preservative: 0.09% Sodium azideConstituents: 99% Tris citrate/phosphate, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EHHADH also known as enoyl-CoA hydratase/3-hydroxyacyl CoA dehydrogenase is a mitochondrial enzyme. Its molecular mass is approximately 82 kDa. EHHADH catalyzes two sequential reactions in the β-oxidation of fatty acids converting L-3-hydroxyacyl-CoA to 3-ketoacyl-CoA. This enzyme expresses mainly in liver and kidney tissues playing a role in lipid metabolism.
Biological function summary
EHHADH acts within the peroxisome a cellular organelle that facilitates lipid metabolism and detoxification processes. EHHADH is a part of the mitochondrial trifunctional protein complex. This complex helps in breaking down long-chain fatty acids highlighting EHHADH's role in energy production.
Pathways
EHHADH engages in the fatty acid β-oxidation pathway and the peroxisomal fatty acid β-oxidation pathway. In these pathways EHHADH works alongside proteins like HADHA and HADHB both of which are part of the trifunctional protein complex. The collaboration between these proteins ensures efficient lipid degradation and energy release.
EHHADH links to disorders such as peroxisomal biogenesis disorders and Zellweger syndrome. Mutations affecting EHHADH or its associated proteins like VLCAD (very-long-chain acyl-CoA dehydrogenase) can disrupt normal mitochondrial functions. This disruption can lead to accumulation of unmetabolized fatty acids contributing to disease progression.